Abstract：Objective: To study the effects of recombinant human brain natriuretic peptide (rhBNP) on myocardial enzymes and N-terminal pro-brain natriuretic peptide (NT-proBNP) in elderly patients with acute decompensated heart failure (ADHF). Methods: A total of 150 elderly ADHF patients admitted to our hospital from June 2017 to June 2018 were enrolled in the study. They were divided into control group and study group by simple random number table method, with 75 cases in each group. Control group was treated with conventional methods while study group was treated with rhBNP on the basis of conventional treatment, and they were treated for 1 week. The efficacy, and cardiac function indexes, 24h urine volume, myocardial enzymes, and NT-proBNP before and after treatment were compared between the two groups, and the occurrence of adverse reactions was monitored. Results: The total post-treatment effective rate in study group was higher than that in control group(P<0.05). The post-treatment evaluation reveals the following facts, compared to pre-treatment: the left ventricular ejection fraction (LVEF) in both groups was higher while the left ventricular end-systolic volume (LVESV) and left ventricular end-diastolic volume (LVEDV) were lower, and the LVEF in study group was higher than that in control group while the LVESV and LVEDV were lower than those in control group (P<0.05). The 24h urine volume in both groups was higher and the 24h urine volume in study group was higher than that in control group (P<0.05).The levels of lactate dehydrogenase (LDH), creatine kinase (CK), creatine kinase isoenzyme MB (CK-MB) and α-hydroxybutyrate dehydrogenase (α-HBD) in both groups were lower and the above indexes in study group were lower than those in control group (P<0.05). The level of NT-proBNP in both groups was lower and the level of NT-proBNP in study group was lower than that in control group (P<0.05). The incidence rates of adverse reactions in both groups during treatment were 18.67% and 21.33% respectively (P>0.05). Conclusion: RhBNP has significant efficacy in the treatment of elderly patients with acute decompensated heart failure. It helps improve the level of myocardial enzymes, increase urine output and improve cardiac function, and it proves to be highly safe and applicable.
孔海英, 杨广龙, 尹琼, 汪凛. rhBNP治疗对老年急性失代偿期心力衰竭患者心肌酶及NT-proBNP的影响[J]. 河北医学, 2020, 26(5): 735-740.
KONG Haiying, YANG Guanglong, YIN Qiong, et al. Effects of RhBNP on Myocardial Enzymes and NT-proBNP in Elderly Patients with Acute Decompensated Heart Failure. HeBei Med, 2020, 26(5): 735-740.
[1] King JB,Shah RU,Sainski-Nguyen A,et al.Effect of inpatient dobutamine vs.milrinone on out-of-hospital mortality in patients with acute decompensated heart failure[J].Pharmacotherapy,2017,37(6):662~672. [2] 姜敏华,敬波,于军,等.新活素对老年急性失代偿期心力衰竭患者心功能、尿量及精神状态的影响[J].国际精神病学杂志,2015,42(3):55~57. [3] 古军恩,李俊,宋启宾.重组人脑利钠肽联合左西孟旦对急性失代偿性心力衰竭的临床研究[J].岭南急诊医学杂志,2016,21(4):320~322. [4] Xu H,Wang B,Meng Q,et al.Effectiveness and safety of recombinant human brain natriuretic peptide in the treatment of acute myocardial infarction in elderly in combination with cardiac failure[J].Pakistan Journal of Medical Sciences,2017,33(3):540~544. [5] 李美娇.重组人脑利钠肽联合托伐普坦治疗对急性失代偿性心力衰竭临床疗效及预后[J].中国疗养医学,2017,26(9):971~973. [6] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会.急性心力衰竭诊断和治疗指南[J].中华心血管病杂志,2010,8(3):605~615. [7] 纪道兵,周心涛,许浩,等.重组人脑钠肽治疗老年急性失代偿期心力衰竭患者的疗效[J].心血管康复医学杂志,2017,26(4):395~398. [8] Takaya Y,Yoshihara F,Yokoyama H,et al.Impact of decreased serum albumin levels on acute kidney injury in patients with acute decompensated heart failure:a potential association of atrial natriuretic peptide[J].Heart&Vessels,2017,32(8):1~12. [9] 李家耀,钟武勇,苏海燕.心肌酶谱水平检测在心力衰竭诊断中的价值[J].转化医学电子杂志,2017,4(8):55~57.
2020, Vol. 26 
冀公网安备13080202000677号